139 related articles for article (PubMed ID: 33382798)
1. Assessing the effects of National Health Insurance reimbursement policy revisions for anti-osteoporotic drugs in Korean women aged 50 or older.
Koo JS; Moon SH; Lee H; Park S; Yu YM; Kang HY
PLoS One; 2020; 15(12):e0244759. PubMed ID: 33382798
[TBL] [Abstract][Full Text] [Related]
2. Management of osteoporosis in women after forearm fracture: data from a French health insurance database.
Erny F; Auvinet A; Chu Miow Lin D; Pioger A; Haguenoer K; Tauveron P; Jacquot F; Rusch E; Goupille P; Mulleman D
Joint Bone Spine; 2015 Jan; 82(1):52-5. PubMed ID: 25241339
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the proportion of patients potentially treated with an anti-osteoporotic drug using the current criteria of the Belgian national social security and the new suggested FRAX criteria.
Bruyère O; Fossi M; Zegels B; Leonori L; Hiligsmann M; Neuprez A; Reginster JY
Rheumatol Int; 2013 Apr; 33(4):973-8. PubMed ID: 22842952
[TBL] [Abstract][Full Text] [Related]
4. Anti-osteoporosis medication treatment pattern after osteoporotic fracture during 2010-2016 in Fujian, China.
Wang X; Li C; He Y; Wang T; Zhang H; Ma Z; Ma H; Zhao H
Arch Osteoporos; 2020 Aug; 15(1):134. PubMed ID: 32820451
[TBL] [Abstract][Full Text] [Related]
5. Gender differences in anti-osteoporosis drug treatment after osteoporotic fractures.
Jung Y; Ko Y; Kim HY; Ha YC; Lee YK; Kim TY; Choo DS; Jang S
J Bone Miner Metab; 2019 Jan; 37(1):134-141. PubMed ID: 29536198
[TBL] [Abstract][Full Text] [Related]
6. Trends and determinants of antiresorptive drug use for osteoporosis among elderly women.
Perreault S; Dragomir A; Desgagné A; Blais L; Rossignol M; Blouin J; Moride Y; Ste-Marie LG; Fernandès JC
Pharmacoepidemiol Drug Saf; 2005 Oct; 14(10):685-95. PubMed ID: 15645517
[TBL] [Abstract][Full Text] [Related]
7. Impact of the Requirement of Bone Mineral Density Evidence on Utilization of Anti-osteoporosis Medications, Clinical Outcome and Medical Expenditures of Patient With Hip Fracture in Taiwan.
Wang CY; Fu SH; Hung CC; Yang RS; Lin JW; Chen HM; Hsiao FY; Shen LJ
Int J Health Policy Manag; 2022 Apr; 11(4):470-478. PubMed ID: 33059424
[TBL] [Abstract][Full Text] [Related]
8. Prescription of anti-osteoporosis medications after hospitalization for hip fracture: a multicentre Italian survey.
Gonnelli S; Caffarelli C; Iolascon G; Bertoldo F; Letizia Mauro G; Patti A; Nuti R
Aging Clin Exp Res; 2017 Oct; 29(5):1031-1037. PubMed ID: 27943127
[TBL] [Abstract][Full Text] [Related]
9. Anti-osteoporosis drug use: too little, too much, or just right? The HUNT study, Norway.
Hoff M; Skurtveit S; Meyer HE; Langhammer A; Søgaard AJ; Syversen U; Skovlund E; Abrahamsen B; Forsmo S; Schei B
Osteoporos Int; 2018 Aug; 29(8):1875-1885. PubMed ID: 29774403
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the efficacy between once-monthly oral ibandronate and risedronate among Korean women with osteoporosis: a nationwide population-based study.
Lee DR; Lee J
Osteoporos Int; 2019 Mar; 30(3):659-666. PubMed ID: 30535785
[TBL] [Abstract][Full Text] [Related]
11. Eleven years secular trend of the initiation of anti-osteoporosis medications and subsequent fractures in Taiwan: From 2008 to 2018.
Yang TH; Wang CY; Fu SH; Chan DC; Chen HM; Lin JW; Huang CF; Yang JJ; Wu CH; Hwang JS; Yang RS
J Formos Med Assoc; 2023; 122 Suppl 1():S36-S44. PubMed ID: 37280138
[TBL] [Abstract][Full Text] [Related]
12. Establishing and evaluating FRAX
Chan DC; McCloskey EV; Chang CB; Lin KP; Lim LC; Tsai KS; Yang RS
J Formos Med Assoc; 2017 Mar; 116(3):161-168. PubMed ID: 27117886
[TBL] [Abstract][Full Text] [Related]
13. Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.
Parthan A; Kruse M; Agodoa I; Silverman S; Orwoll E
Bone; 2014 Feb; 59():105-13. PubMed ID: 24231131
[TBL] [Abstract][Full Text] [Related]
14. Estimating medical expenditure associated with osteoporotic hip fracture in elderly Korean women based on the National Health Insurance Claims Database 2002-2004.
Kang HY; Park SE; Kang DR; Kim JY; Jang YH; Choi WJ; Moon SH; Yang KH; Park JY; Kwon SY
Value Health; 2009; 12 Suppl 3():S93-6. PubMed ID: 20586992
[TBL] [Abstract][Full Text] [Related]
15. Influence of insurance benefit criteria on the administration rate of osteoporosis drugs in postmenopausal females.
Lee JH; Lee YH; Moon SH; Lee YS;
Clin Orthop Surg; 2014 Mar; 6(1):56-61. PubMed ID: 24605190
[TBL] [Abstract][Full Text] [Related]
16. Factors associated with treatment of women with osteoporosis or osteopenia from a national survey.
Meadows ES; Mitchell BD; Bolge SC; Johnston JA; Col NF
BMC Womens Health; 2012 Jan; 12():1. PubMed ID: 22225919
[TBL] [Abstract][Full Text] [Related]
17. Anti-osteoporotic treatments in France: initiation, persistence and switches over 6 years of follow-up.
Belhassen M; Confavreux CB; Cortet B; Lamezec L; Ginoux M; Van Ganse E
Osteoporos Int; 2017 Mar; 28(3):853-862. PubMed ID: 27766368
[TBL] [Abstract][Full Text] [Related]
18. Use of teriparatide in osteoporotic fracture patients.
Collinge C; Favela J
Injury; 2016 Jan; 47 Suppl 1():S36-8. PubMed ID: 26768289
[TBL] [Abstract][Full Text] [Related]
19. Development of a Korean Fracture Risk Score (KFRS) for Predicting Osteoporotic Fracture Risk: Analysis of Data from the Korean National Health Insurance Service.
Kim HY; Jang EJ; Park B; Kim TY; Shin SA; Ha YC; Jang S
PLoS One; 2016; 11(7):e0158918. PubMed ID: 27399597
[TBL] [Abstract][Full Text] [Related]
20. Estimates of hip fracture incidence in Japan using the National Health Insurance Claim Database in 2012-2015.
Tamaki J; Fujimori K; Ikehara S; Kamiya K; Nakatoh S; Okimoto N; Ogawa S; Ishii S; Iki M;
Osteoporos Int; 2019 May; 30(5):975-983. PubMed ID: 30648192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
